DEERFIELD, Ill., March 23 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced the launch of generic azithromycin for injection (Pfizer/Zithromax(R)), a commonly used antibiotic. The launch marks the first time Baxter has been granted exclusive authorization by a pharmaceutical company to market a generic version of their brand product. Pfizer will manufacture generic azithromycin for injection and Baxter will sell and market the product in the United States.
“We are pleased that Pfizer selected us as their exclusive authorized generic for this important injectable antibiotic,” said Daniel Tasse, general manager of Baxter’s Anesthesia, Critical Care & Oncology division, part of Baxter’s Medication Delivery business. “Azithromycin, which is the first authorized generic Baxter has pursued, complements our existing portfolio of products that includes enhanced packaging, proprietary drugs and other generics.”
Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. . Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients’ lives.
Baxter Healthcare Corporation
CONTACT: Media, Erin Gardiner, +1-847-948-4210, or Deborah Spak,+1-847-948-2349, or Investors, Mary Kay Ladone, +1-847-948-3371, or ClareSullivan, +1-847-948-3085, all of Baxter Healthcare Corporation
Web site: http://www.baxter.com/
